Stevens Capital Management LP Buys Shares of 6,849 Amgen Inc. (NASDAQ:AMGN)

Stevens Capital Management LP acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 6,849 shares of the medical research company's stock, valued at approximately $1,785,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Centricity Wealth Management LLC acquired a new position in Amgen in the fourth quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter valued at $29,000. Synergy Investment Management LLC acquired a new position in shares of Amgen during the 4th quarter valued at $34,000. Atala Financial Inc bought a new position in Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen in the fourth quarter worth $36,000. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AMGN shares. Bank of America upped their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Piper Sandler Companies reaffirmed an "overweight" rating and set a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Amgen has a consensus rating of "Hold" and an average price target of $314.04.

Remove Ads

Insider Buying and Selling at Amgen

In related news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last three months. 0.69% of the stock is currently owned by insiders.

Amgen Stock Performance

Shares of AMGN traded up $0.96 on Thursday, reaching $306.67. 187,810 shares of the company's stock traded hands, compared to its average volume of 2,536,202. The stock's 50 day simple moving average is $299.66 and its two-hundred day simple moving average is $298.46. The stock has a market cap of $164.75 billion, a PE ratio of 40.62, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.